{
    "2021-06-07": [
        [
            {
                "time": "2023-07-14",
                "original_text": "Novo Nordisk (NVO) Semaglutide Gets FDA Nod for Obesity",
                "features": {
                    "keywords": [
                        "Semaglutide",
                        "FDA",
                        "Obesity",
                        "Approval"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-07-14",
                "original_text": "Novo Nordisk's Semaglutide Gets FDA Approval to Tackle Obesity",
                "features": {
                    "keywords": [
                        "Semaglutide",
                        "FDA",
                        "Obesity",
                        "Approval"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-07-14",
                "original_text": "Novo Nordisk A/S â€“ Share repurchase programme",
                "features": {
                    "keywords": [
                        "Share",
                        "repurchase",
                        "programme"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "finance",
                        "corporate actions"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-07-14",
                "original_text": "UPDATE 1-Risk of patient overlap between Wegovy and Saxenda obesity drugs, Novo says",
                "features": {
                    "keywords": [
                        "Wegovy",
                        "Saxenda",
                        "patient overlap",
                        "obesity drugs"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2023-07-14",
                "original_text": "Risk of patient overlap between Wegovy and Saxenda obesity drugs, Novo says",
                "features": {
                    "keywords": [
                        "Wegovy",
                        "Saxenda",
                        "patient overlap",
                        "obesity drugs"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}